Kezar Life Sciences announces positive top-line results from the Phase 2 MISSION study evaluating zetomipzomib for the treatment of patients with lupus nephritis

11 of 17 patients (64.7%) achieves a general renal response 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months Six of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less, at 6 months Zetomipzomib continues to show a favorable safety and tolerability profile when … Read more

Cogent Biosciences announces positive initial clinical data from the ongoing Phase 2 APEX study evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).

Cogent Biosciences, Inc. All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89% regardless of prior treatment with the KIT-D816V inhibitor All patients who underwent bone marrow biopsy scored ≥50% reduction in bone marrow mast cells and reduction in allelic fraction of variant KIT D816V in blood (VAF) … Read more